الفهرس Only 14 pages are availabe for public view
 |  | from | 152 |  |  |
| | | from | 152 | | |
Abstract
Hepatic fibrosis is an inclusion indicator for treatment and a major independent predictor of treatment response in patients with chronic hepatitis C. Liver biopsy, considered as the 2gold standard3 for evaluating liver fibrosis, has carried some drawbacks. Currently used noninvasive predictors of fibrosis are considered less accurate than liver biopsy. To evaluate effectiveness of demographic and biochemical markers as a simple non invasive model for prediction of significant hepatic fibrosis in patients with chronic hepatitis C virus (HCV) infection and comparing its diagnostic performance to liver biopsy. Cross sectional prospective study including 200 Egyptian patients with chronic hepatitis C. Routine pre-treatment workup, special tests (Alpha 2 macroglobulin, carbohydrate 19.9 Antigen) and reference needle liver biopsy were performed. Fib - 4, Egyscore, AST to platelet ratio index (APRI), Göteborg University Cirrhosis Index (GUCI) were validated. Patients were divided into two groups, first with insignificant fibrosis (< F2), and second with significant fibrosis ({u2265}F2) using the Metavir score